Home ยป CTSU ECOG E1305: Head and Neck Cancer

CTSU ECOG E1305: Head and Neck Cancer

CTSU ECOG E1305: A PHASE III RANDOMIZED TRIAL OF CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER

Approval Date: 8/31/2010

Principal Investigator: Padmaja Venuturumilli, MD

The purpose of this study is to evaluate if adding bevacizumab to standard chemotherapy for recurrent or metastatic head and neck cancer produces results that are better than those we would ordinarily expect.

Eligibility:

  • Confirmed squamous cell carcinoma of the head and neck (SCCHN)
  • Metastatic or recurrent SCCHN of the head--incurable by surgery or radiation
  • No chemotherapy for recurrent or metastatic SCCHN

Contact Person:
Royal Oak
248-551-7695

Troy
248-964-0606

Status of Clinical Trial:
open and enrolling